Assignee
ROCHE GLYCART AG
CH·45 granted patents·74 pending applications·551 citations·filing 2004–2024
Top patents by PatentIndex Score
119 records- 0198US11130822B2ImmunoconjugatesROCHE GLYCART AG·Filed 2019·Granted Sep 28, 2021·16 cites·24 claims
- 0298US10316104B2ImmunoconjugatesROCHE GLYCART AG·Filed 2016·Granted Jun 11, 2019·30 cites·23 claims
- 0398US10202464B2ImmunoconjugatesROCHE GLYCART AG·Filed 2016·Granted Feb 12, 2019·30 cites·3 claims
- 0498US10184009B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2017·Granted Jan 22, 2019·37 cites·30 claims
- 0598US8021856B2Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicityROCHE GLYCART AG·Filed 2005·Granted Sep 20, 2011·51 cites·19 claims
- 0697US10577429B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2015·Granted Mar 3, 2020·17 cites·28 claims
- 0797US10323098B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2016·Granted Jun 18, 2019·25 cites·30 claims
- 0897US10253110B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2015·Granted Apr 9, 2019·15 cites·17 claims
- 0997US9695233B2Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseasesROCHE GLYCART AG·Filed 2013·Granted Jul 4, 2017·44 cites·11 claims
- 1096US11111312B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2018·Granted Sep 7, 2021·8 cites·5 claims
- 1196US9526797B2Combination IL-2 immunoconjugate therapyROCHE GLYCART AG·Filed 2013·Granted Dec 27, 2016·57 cites·20 claims
- 1296US9206260B2Anti-CEA antibodiesROCHE GLYCART AG·Filed 2013·Granted Dec 8, 2015·23 cites·13 claims
- 1395US9346872B2Interleukin-10 fusion proteinsROCHE GLYCART AG·Filed 2013·Granted May 24, 2016·43 cites·22 claims
- 1494US11332545B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2019·Granted May 17, 2022·6 cites·9 claims
- 1593US10781258B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Granted Sep 22, 2020·4 cites·39 claims
- 1693US10603360B2Combination IL-2 immunoconjugate therapyROCHE GLYCART AG·Filed 2016·Granted Mar 31, 2020·13 cites·22 claims
- 1793US10155815B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2014·Granted Dec 18, 2018·12 cites·46 claims
- 1892US9771427B2ASGPR antibodies and uses thereofROCHE GLYCART AG·Filed 2013·Granted Sep 26, 2017·16 cites·25 claims
- 1991US11459404B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2017·Granted Oct 4, 2022·5 cites·1 claims
- 2091US10683345B2Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseasesROCHE GLYCART AG·Filed 2017·Granted Jun 16, 2020·5 cites·16 claims
- 2190US11214622B2Antibodies specific for DR5 and methods of useROCHE GLYCART AG·Filed 2018·Granted Jan 4, 2022·6 cites·13 claims
- 2290US9926379B2Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5ROCHE GLYCART AG·Filed 2014·Granted Mar 27, 2018·17 cites·28 claims
- 2389US10562949B2Interleukin-2 fusion proteins and uses thereofROCHE GLYCART AG·Filed 2017·Granted Feb 18, 2020·6 cites·10 claims
- 2488US10040843B2Interleukin-10 fusion proteins and uses thereofROCHE GLYCART AG·Filed 2016·Granted Aug 7, 2018·7 cites·22 claims
- 2588US9650442B2Bispecific anti-EGFR/anti IGF-1R antibodiesROCHE GLYCART AG·Filed 2014·Granted May 16, 2017·14 cites·6 claims
- 2688US9321843B2Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicityROCHE GLYCART AG·Filed 2015·Granted Apr 26, 2016·3 cites·43 claims
- 2788US9309317B2Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereofROCHE GLYCART AG·Filed 2013·Granted Apr 12, 2016·6 cites·44 claims
- 2888US2024301079A1Antigen binding molecules with increased fc receptor binding affinity and effector functionROCHE GLYCART AG·Filed 2023·Application pending·0 cites
- 2988US2025043028A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2024·Application pending·0 cites
- 3087US10087250B2Fc-free antibodies comprising two fab-fragments and methods of useROCHE GLYCART AG·Filed 2013·Granted Oct 2, 2018·10 cites·12 claims
- 3186US2023365711A1Anti-cea antibodiesROCHE GLYCART AG·Filed 2023·Application pending·0 cites
- 3286US2024425616A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2024·Application pending·0 cites
- 3385US10781257B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Granted Sep 22, 2020·1 cites·34 claims
- 3485US9346886B2Humanized anti-CDCP1 antibodiesROCHE GLYCART AG·Filed 2012·Granted May 24, 2016·8 cites·2 claims
- 3584US2023340160A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2023·Application pending·0 cites
- 3684US2024018259A1Antibody fc variantsROCHE GLYCART AG·Filed 2023·Application pending·0 cites
- 3783US12286486B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2022·Granted Apr 29, 2025·0 cites·17 claims
- 3883US11365232B2Interleukin-2 fusion proteins and uses thereofROCHE GLYCART AG·Filed 2020·Granted Jun 21, 2022·1 cites·6 claims
- 3983US2023076791A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2022·Application pending·0 cites
- 4081US2023212303A1Antigen binding molecules with increased fc receptor binding affinity and effector functionROCHE GLYCART AG·Filed 2022·Application pending·0 cites
- 4181US2022064296A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 4279US2022242971A1Novel immunoconjugatesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 4379US2022002441A1Anti-cea antibodiesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 4478US2021253703A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 4578US2021253704A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 4677US2021101979A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2020·Application pending·0 cites
- 4776US8859234B2Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector functionROCHE GLYCART AG·Filed 2013·Granted Oct 14, 2014·3 cites·37 claims
- 4876US8367374B2Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector functionROCHE GLYCART AG·Filed 2004·Granted Feb 5, 2013·9 cites·33 claims
- 4975US2020385470A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2020·Application pending·0 cites
- 5075US2020332012A1Antigen Binding Molecules That Bind EGFR, Vectors Encoding Same, and Uses ThereofROCHE GLYCART AG·Filed 2019·Application pending·0 cites
Showing the top 50 of 119 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ROCHE GLYCART AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →